[
	{
		"title": "Keynote Takeaways",
		"description": "All pharmas are currently actively pursuing cancer immunotherapy approaches. Attrition rate at 90% - as high as ever. Costs $1.8 Bn/approved drug.",
		"author":"Dimitri",
    "time": "04/13/2015 4:55PM"
	},
  {
    "title": "Oncology Deal Room",
    "description": "Genentech MPDL3280A drug looks promising in PhIII.",
    "author":"Dimitri",
    "time": "04/11/2015 4:55PM"
  }

]